Trading News

Moderna Stock Is Spiking Because an Omicron Covid Vaccine Could Be Ready in Early 2022


Moderna stock was rising sharply in premarket trading Monday after the vaccine maker said a reformulated vaccine to tackle the Omicron covid variant could be ready in early 2022.

Moderna (ticker: MRNA) rose more than 9% to $359.80 in premarket trading Monday. The stock gained 20.6% on Friday after Moderna said it was working to rapidly advance an Omicron-specific booster candidate, targeting 60 to 90 days for clinical testing to begin.


European markets climb despite global concern over omicron variant

Previous article

Citi downgrades Merck to neutral, says drug pipeline struggles will hold stock back

Next article

You may also like


Leave a reply

Your email address will not be published.

More in Trading News